Tag Archives: ML8500

Modulight Spotlights: LASER-SHARP RESEARCH – September 2024

September 23, 2024 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – September 2024 University of Maryland and Modulight have published together a new research study about the mechanisms of cancer drug resistance. Drug resistance is a leading cause of treatment failure and often has dramatic consequences for survival of cancer patients. Cancer cells have developed various ways to protect themselves from drugs. When several clinically used photoactive drugs were studied, it was shown that some of them were being actively pumped out by cancer cells, thus likely limiting the full therapeutic potential Continue reading →

Development of thermosensitive liposomes with the help of ML8500

March 13, 2024 by Modulight Content
No comments
Background The proper delivery and release of therapeutic drugs to a specific site or cell type is one of the main challenges in the treatment of diseases. Liposomes, which are vesicles composed of lipids, serve as carriers for drug delivery thanks to their long circulation time. This results to reduced toxicity in healthy tissues and improved therapeutic efficacy of encapsulated drugs. However, conventional liposomes can often be even too stabile, leading to insufficient drug release at the target site. Light activation can offer a solution Continue reading →Customer case Pharmaceutical Nanotechnology Group at University of Helsinki is specialized in top-level pharmaceutical research. Led by Professor Timo Laaksonen, the group focuses on controlled drug release and delivery using modern methods and materials. Particular interest lies in using light to both monitor nanomaterial behavior and to trigger e.g. drug release processes. Modulight products: ML8500, ML6600, MLAKIT   Prof. Timo Laaksonen Dr. Tatu Lajunen Laser use: Light-triggered drug release studies from light-activated liposomes. ML8500 with 808 nm wavelength was used to induce the release of calcein from liposomes under Continue reading →

Co-Packaged PARP inhibitor and photosensitizer for targeted photo-chemotherapy of 3D ovarian cancer spheroids

February 6, 2024 by Modulight
No comments
Published in: Cell & Bioscience Authors: Aaron Sorrin, Anika Dasgupta, Kathryn McNaughton, Carla Arnau Del Valle, Keri Zhou, Cindy Liu, Dana M. Roque & Huang Chiao Huang Within the last decade, poly(ADP-ribose) polymerase inhibitors (PARPi) have emerged in the clinic as an effective treatment for numerous malignancies. Preclinical data have demonstrated powerful combination effects of PARPi paired with photodynamic therapy (PDT), which involves light-activation of specialized dyes (photosensitizers) to stimulate cancer cell death through reactive oxygen species generation. In this study, a novel combination strategy was Continue reading →

Development of Robust Cationic Light-Activated Thermosensitive Liposomes: Choosing the Right Lipids

October 24, 2023 by Modulight Content
No comments
Published in: Molecular Pharmaceutics Authors: Puja Gangurde, Mohammad Mahmoudzadeh, Zahra Gounani, Artturi Koivuniemi, Patrick Laurén, Tatu Lajunen, Timo Laaksonen  Published in: Molecular Pharmaceutics Authors: Puja Gangurde, Mohammad Mahmoudzadeh, Zahra Gounani, Artturi Koivuniemi, Patrick Laurén, Tatu Lajunen, Timo Laaksonen The study investigated the impact of different lipids on liposome stability. It was found that substituting unsaturated lipid with equal amount of saturated lipid, resulted in stable liposomes that were highly responsive to light triggered release. ML8500 was used for light-activated release of calcein from liposomes.   Read the article here

Light-induced cytotoxicity in cells utilizing an automated well plate illuminator

March 7, 2023 by Modulight Content
No comments
Presented in: SPIE BIOS 2023 Authors: Laura Vesala, Robert Perttilä, Elias Kokko, Johannes Kivelä, Lasse Orsila, Petteri Uusimaa    Presented in: SPIE BIOS 2023 Authors: Laura Vesala, Robert Perttilä, Elias Kokko, Johannes Kivelä, Lasse Orsila, Petteri Uusimaa   Delivering therapeutic drug molecules to the target site and releasing the cargo site-specifically is of major interest in biomedicine. To carry and release drugs to specific target tissues, different nanotechnology approaches have been utilized. These include light-sensitive liposomal carriers, which have been engineered to release cargo from their aqueous cores when illuminated by certain wavelengths of laser light. To study drug release parameters in vitro, Modulight Continue reading →

A Non-Invasive Deep Photoablation Technique to Inhibit DCIS Progression and Induce Antitumor Immunity

November 23, 2022 by Modulight Content
No comments
Published in: Cancers Authors: Kensuke Kaneko, Hiroshi Nagata, Xiao-Yi Yang, Joshua Ginzel, Zachary Hartman, Jeffrey Everitt, Philip Hughes, Timothy Haystead, Michael Morse, Herbert Kim Lyerly, Takuya Osada    Published in: Cancers Authors: Kensuke Kaneko, Hiroshi Nagata, Xiao-Yi Yang, Joshua Ginzel, Zachary Hartman, Jeffrey Everitt, Philip Hughes, Timothy Haystead, Michael Morse, Herbert Kim Lyerly, Takuya Osada   The study investigated HSP90-targeted PDT for minimally invasive treatment of ductal carcinoma in situ (DCIS), benign breast cancer condition that has potential to progress into breast cancer. PDT with ML8500 combined to ML7710 resulted in effective in vitro cytotoxicity and with ML7710 in vivo, which was further potentiated with PD-L1 immune checkpoint inhibitors.   Read the article Continue reading →

Development of heat shock protein 90-targeted PDT for inflammatory breast cancer

May 17, 2021 by Modulight Content
No comments
Motivation of the study In photodynamic therapy (PDT), systemically administered photosensitizer is activated within the tumor using focused near-infrared light, typically a laser with a wavelength matching the absorption peak of the photosensitizer. Several photosensitizers have been clinically approved for the treatment of different cancers; however, their accumulation is non-tumor exclusive which exposes healthy tissues to side effects like daylight-induced phototoxicity. A promising strategy to improve tumor selectivity is to couple photosensitizer to a tumor-targeting agent that binds to a specific antigen expressed on the Continue reading →Customer case Research by: Duke University, founded in 1924, is one of the leading and wealthiest private research universities in the USA. The most notable Duke alumni is President Richard Nixon. Research at Duke University has been awarded with several Nobel prizes in recent years for groundbreaking discoveries in biochemistry and medicine, such as G-protein coupled receptors, DNA mismatch repair, and cellular regulation of hypoxia. Modulight products: ML8500, ML7710 (665 nm, 689 nm, 750 nm) Laser use: Heat shock protein 90-targeted PDT for breast cancer Continue reading →

In vitro illumination using ML8500: osmium-based anticancer photosensitizer with highest hypoxic activity reported to date

March 26, 2021 by Modulight Content
No comments
  Sherri McFarland discussing how ML8500 is supporting her research   Study protocol to determine wavelength, fluence, and irradiance activities of Os-4T:   Key observations Illumination parameters significantly affected the phototoxicity of Os-4T. The green light (525 nm) was more effective than the red light (630 nm) at lower fluences, while the maximal potency was achieved at both wavelengths when using fluences higher than 100 J/cm2. Irradiance affected the potency with both the red and the green light that were more effective when lower irradiances Continue reading →Customer case Research by: University of Texas at Arlington, US. One of the leading groups in photoactive drug discovery. Developed first clinical-level rubidium-based PS (TLD-1433), now in Theralase-sponsored Phase 2 trials for bladder cancer. Modulight products: ML8500 (445 nm, 525 nm, 630 nm, 753 nm, 810 nm) Laser use: Photoactive drug discovery Link to the study: Prof. Sherri McFarland Research topics: Medicinal inorganic chemistry and drug discovery. Special interest in the synthesis of novel transition metal complexes and studying their interactions with light for the purpose Continue reading →

Near-infrared Absorbing Ru(II) Complexes Act as Immunoprotective Photodynamic Therapy (PDT) Agents Against Aggressive Melanoma

September 9, 2020 by Modulight
No comments
Published in: Chemical Science Authors: Liubov M. Lifshits, A. Roque III, Prathyusha Konda, Susan Monro, Houston D. Cole, David von Dohlen, Susy Kim, Gagan Deep, Randolph P. Thummel, Colin G. Cameron, Shashi Gujar, Sherri A. McFarland    Published in: Chemical Science Authors: Liubov M. Lifshits, A. Roque III, Prathyusha Konda, Susan Monro, Houston D. Cole, David von Dohlen, Susy Kim, Gagan Deep, Randolph P. Thummel, Colin G. Cameron, Shashi Gujar, Sherri A. McFarland   9 novel Ru-based coordination complexes with different ligands were systematically synthetized and explored with aim to long wavelengths (>700 nm – >1000 nm depending on the compound) and high singlet oxygen quentum yeild for melanoma PDT. Light dosimetry and phototoxicities were studied in vitro (ML8500) and in vivo. Continue reading →

Breaking the barrier: an osmium photosensitizer with unprecedented hypoxic phototoxicity for real world photodynamic therapy

August 3, 2020 by Modulight
No comments
Published in: Chemical Science Authors: John A. Roque III, Patrick C. Barrett, Houston D. Cole, Liubov M. Lifshits, Ge Shi, Susan Monro, David von Dohlen, Susy Kim, Nino Russo, Gagan Deep, Colin G. Cameron, Marta E. Alberto, Sherri A. McFarland    Published in: Chemical Science Authors: John A. Roque III, Patrick C. Barrett, Houston D. Cole, Liubov M. Lifshits, Ge Shi, Susan Monro, David von Dohlen, Susy Kim, Nino Russo, Gagan Deep, Colin G. Cameron, Marta E. Alberto, Sherri A. McFarland   ML8500 was used for specialized dosimetry studies in the development of the osmium-based PS using similar drug development strategy as for the analogous Ru(II) series that resulted in TLD1433 (first metal complex in clinical trials). The Os-compound approaches the ideal properties with multi-wavelength activation Continue reading →